A recent panel discussion hosted by Biopharma Excellence featured experts in biotech and the evolving regulatory environment to talk about the challenge of achieving statistical significance with novel and highly targeted therapies, especially for rare/ultra-rare diseases.
Daniel O’Connor of the UK’s MHRA noted that the challenge of achieving statistical significance when target populations are tiny is...